# É. Hachulla

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/e-hachulla/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,217 |
| Field | Systemic Sclerosis and Related Diseases |
| h-index | 120 |
| i10-index | 631 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5018486655 |
| ORCID iD | https://orcid.org/0000-0001-7432-847X |
| Works | 1,684 |

## Researcher papers

- [Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients](https://scholariq.org/papers/antiphospholipid-syndrome-clinical-and-immunologic-manifestations-and-patterns/)
- [Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients](https://scholariq.org/papers/morbidity-and-mortality-in-the-antiphospholipid-syndrome-during-a-10-year-period/)
- [Mapping and predicting mortality from systemic sclerosis](https://scholariq.org/papers/mapping-and-predicting-mortality-from-systemic-sclerosis/)
- [Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry](https://scholariq.org/papers/factors-associated-with-covid-19-related-death-in-people-with-rheumatic-diseases/)
- [Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study](https://scholariq.org/papers/oral-pharmacological-chaperone-migalastat-compared-with-enzyme-replacement/)
- [Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database](https://scholariq.org/papers/progressive-interstitial-lung-disease-in-patients-with-systemic-sclerosis/)
- [Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies](https://scholariq.org/papers/autoimmune-and-inflammatory-manifestations-occur-frequently-in-patients-with/)
- [COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study](https://scholariq.org/papers/covid-19-outcomes-in-patients-with-inflammatory-rheumatic-and-musculoskeletal/)
- [Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis](https://scholariq.org/papers/long-term-outcomes-and-prognostic-factors-of-complications-in-takayasu-arteritis/)
- [Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients](https://scholariq.org/papers/long-term-efficacy-and-safety-of-rituximab-in-igg4-related-disease-data-from-a/)
- [Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients](https://scholariq.org/papers/efficacy-of-anti-tnf-alpha-in-severe-and-or-refractory-behcet-s-disease/)
- [Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study](https://scholariq.org/papers/long-term-safety-and-efficacy-of-patisiran-for-hereditary-transthyretin-mediated/)

## Researcher topics

- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Salivary Gland Disorders and Functions](https://scholariq.org/topics/salivary-gland-disorders-and-functions/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.